Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates-Reference-Cited by-同舟云学术

Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates

Published:1997-05 Issue:7 Volume:13 Page:575-582
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

KESSLER JOSEPH A.,McKENNA PHILIP M.,EMINI EMILIO A.,CHAN CHRISTINE P.,PATEL MAYUR D.,GUPTA SUNIL K.,MARK GEORGE E.,BARBAS CARLOS F.,BURTON DENNIS R.,CONLEY ANTHONY J.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.1997.13.575

Reference26 articles.

1. Monoclonal Antibodies to the C4 Region of Human Immunodeficiency Virus Type 1 gp120: Use in Topological Analysis of a CD4 Binding Site

2. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

3. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120

4. A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities;Vaccines;2022-03-02

2. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41;Viruses;2019-08-01

3. Polyreactive antibodies in anti-HIV-1 responses.;Current Molecular Medicine;2018-07-20

4. Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization;Japanese Journal of Infectious Diseases;2016

5. Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera;BMC Immunology;2015-04-28